Quintessence Biosciences, Inc.

Who is Quintessence Biosciences?

What is the EVade™ Ribonuclease Technology?

How was the EVade™ Ribonuclease Technology Discovered?

Quintessence Biosciences, Inc.
505 South Rosa Road
Madison, Wisconsin 53719 USA
Phone: +1-608.441.2950
Fax: +1-608.441.2952

Management

Business Board

Science Board

Careers

Management

Mr. Ralph Kauten, Chairman, CEO

Ralph Kauten serves as Chief Executive Officer of Quintessence Biosciences, Inc. In this role, Mr. Kauten brings together the resources necessary to build the company and managing the resources to achieve commercial success. Principal among these resources are 1) finances (both equity and debt) and 2) personnel to fill the open positions on the management team. Before joining Quintessence, Mr. Kauten spent 20 years working in various technical and managerial positions in the biotechnology industry. Most recently, Mr. Kauten was Chairman and President of PanVera Corporation, a drug discovery company providing innovative new products consisting of human drug target proteins and assays for high throughput screening. Mr. Kauten was one of three founders of PanVera, which is located in Madison, Wisconsin. Under Mr. Kauten's leadership, PanVera grew from a start-up company in 1992 with three employees to an award winning, rapidly growing and profitable company. In recognition of his performance as leader of PanVera, Mr. Kauten received the Ernst & Young Entrepreneur of the Year Award in 2001. Prior to PanVera, Mr. Kauten served as Vice President Finance, Chief Financial Officer, and Board Member at Promega Corporation. He played a leading role at Promega from the company's early days and was responsible for securing financing as well as overseeing the financial and administrative aspects of worldwide operations. Mr. Kauten has also served as a founder of Mirus Corporation a gene delivery company located in Madison, Wisconsin and continues to serve as Chairman of the Board of Directors. Mr. Kauten has Bachelor and Masters degrees in Business Administration.

Dr. Laura Strong, President and COO

Laura E. Strong, Ph.D., serves the Company as President and Chief Operating Officer. In this position, Dr. Strong is responsible for developing and executing the product development plan and overseeing the development of the human clinical plans for the Company’s drug products. Further Dr. Strong is responsible for developing relationships with current and future customers and collaborators.

As a National Institutes of Health predoctoral fellow, Dr. Strong earned a Ph.D. in organic chemistry at the University of Wisconsin–Madison. While at the University of Wisconsin, Dr. Strong was responsible for leading a team in developing multivalent drugs using synthetic polymers to address the impact of multimerization (aggregation) of cell-surface receptors in biological processes related to disease states including cancer. Dr. Strong is co-author of fourteen publications and co-inventor on four patents. She has completed Executive Education coursework at the University of Wisconsin–Madison Business School in Financial and Project Management.